Timothy P. Hughes

Research interests

Publications

• A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

  Blood · 2021 · https://doi.org/10.1182/blood.2020009984

• Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1902328

• Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1609324

• Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1403088

• Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

  Blood · 2013 · https://doi.org/10.1182/blood-2013-06-510396

• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

  Blood · 2013 · https://doi.org/10.1182/blood-2013-05-501569

• Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

  Leukemia · 2012 · https://doi.org/10.1038/leu.2012.85

• Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

  The Lancet Oncology · 2011 · https://doi.org/10.1016/s1470-2045(11)70201-7

• Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2009.25.3724

• Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

  Leukemia · 2009 · 10.1038/leu.2009.38

• Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2007.14.3339

• Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2009.25.0779

• Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

  Leukemia · 2008 · https://doi.org/10.1038/leu.2008.84

• Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

  Blood · 2007 · https://doi.org/10.1182/blood-2006-11-056028

• Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

  Blood · 2006 · https://doi.org/10.1182/blood-2006-09-047266

• Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

  New England Journal of Medicine · 2006 · 10.1056/nejmoa062867

• Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

  New England Journal of Medicine · 2003 · 10.1056/nejmoa022457

• Experimental Campylobacter jejuni Infection in Humans

  The Journal of Infectious Diseases · 1988 · 10.1093/infdis/157.3.472

• Experimental Campylobacter Jejuni Infection in Humans

  Journal · 1988 · 10.21236/ada265410

Current projects

No projects listed.